生物制药公司89Bio, Inc.（股票代码：ETNB）今日盘中股价大跌5.65%，引发投资者关注。这一显著跌幅主要源于公司最新发布的季度财报未能达到分析师预期。
根据89Bio公布的财报，截至6月30日的季度调整后每股亏损为71美分，远低于分析师平均预期的49美分亏损。公司当季亏损高达1.115亿美元，而收入仍为零。这一业绩表现明显低于市场预期，导致投资者信心受挫。
值得注意的是，89Bio今年以来的股价表现仍相对强劲，截至上一季度累计上涨21.2%。然而，公司连续几个季度未能达到盈利预期，可能引发市场对其长期发展前景的担忧。尽管如此，分析师对该公司的平均评级仍维持在"买入"，12个月目标价中位数为28.00美元，较当前股价有显著上涨空间。这表明尽管短期面临挑战，市场对89Bio的长期发展仍持相对乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.